Robin M.J.M. van Geel

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 328 citations · Full text

Tumor Biology, Purpose Azd1775, Medicine +15

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 263 citations · Full text

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer

Robin M.J.M. van Geel, Josep Tabernero, Élena Elez et al. · Cancer Discovery · 2017 · 226 citations · Full text

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer

Daniele Oddo, Erin M. Sennott, Ludovic Barault et al. · Cancer Research · 2016 · 119 citations · Full text

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF-</i>mutant colorectal cancer (<i>BRAFm</i> CRC).

Josep Tabernero, Robin M.J.M. van Geel, Tormod Kyrre Guren et al. · Journal of Clinical Oncology · 2016 · 96 citations

Immunology, Pathology, Pharmacotherapy +16